[go: up one dir, main page]

KR970701708A - 9-데옥소탁산 화합물(9-Deoxotaxane compounds) - Google Patents

9-데옥소탁산 화합물(9-Deoxotaxane compounds)

Info

Publication number
KR970701708A
KR970701708A KR1019960705045A KR19960705045A KR970701708A KR 970701708 A KR970701708 A KR 970701708A KR 1019960705045 A KR1019960705045 A KR 1019960705045A KR 19960705045 A KR19960705045 A KR 19960705045A KR 970701708 A KR970701708 A KR 970701708A
Authority
KR
South Korea
Prior art keywords
iii
compound
hydrogen
deoxy
acetyl
Prior art date
Application number
KR1019960705045A
Other languages
English (en)
Inventor
래리 엘. 클레인
클린턴 엠. 융
레핑 리
Original Assignee
브록 챨스 엠.
애보트 래보라토리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브록 챨스 엠., 애보트 래보라토리즈 filed Critical 브록 챨스 엠.
Publication of KR970701708A publication Critical patent/KR970701708A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

본 발명은 하기 화학식 (2)의 화합물, 이의 제조방법, 이 화합물을 함유하는 약제학적 조성물 및 종양 성장을 억제하기 위해 이들을 사용하는 방법에 관한 것이다.
위의 화학식 (2)에서, -OR1은 알카노일 또일 파클리탁셀의 C-13 측쇄이고, R2, R3및 R6은 다양한 조합으로 탈산소화되거나 수소일 수 있으며, R4및 R5는 아실 그룹이다.

Description

9-데옥소탁산 화합물(9-Deoxotaxane compounds)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 하기 화학식 (2)의 화합물 또는 이의 프로드럭(prodrug).
    위의 화학식 (2)에서, R1은 알카노일 또는 식
    의 라디칼(여기서, R7은 수소, 알킬, 페닐, 치환된 페닐, 알콕시, 치환된 알콕시, 아미노, 치환된 아미노, 페녹시 및 치환된 페녹시로 이루어진 그룹으로부터 선택되고, R8은 수소, 알킬, 하이드록시알킬, 알콕시알킬, 아미노알킬, 페닐, 치환된 페닐, α-나프틸, β-나프틸 및 헤테로아릴로 이루어진 그룹으로부터 선택되며, R9는 수소, 알카노일, 치환된 알카노일 및 아미노알카노일로 이루어진 그룹으로부터 선택된다)이고, R2, R3및 R6은 독립적으로 수소, 하이드록시, 알콕시, 아미노알카노일 및 알카노일옥시로 이루어진 그룹으로부터 선택되며, R4는 알킬, 알카노일, 아미노알카노일 및 아로일로 이루어진 그룹으로부터 선택되고, R5는 알킬, 알카노일, 아미노알카노일 및 아로일로 이루어진 그룹으로부터 선택된다.
  2. 제1항에 있어서, R1이 식
    또는의 라디칼인 화합물.
  3. 제1항에 있어서, R2가 수소인 화합물.
  4. 제2항에 있어서, R2가 수소인 화합물.
  5. 제1항에 있어서, R3이 수소인 화합물.
  6. 제2항에 있어서, R3이 수소인 화합물.
  7. 제2항에 있어서, R2와 R3이 둘다 수소인 화합물.
  8. 제2항에 있어서, R2와 R3이 둘다 수소인 화합물.
  9. 제1항에 있어서, R1과 R4가 아세틸이고 R2가 아세톡시이며 R5가 하이드록시인 화합물.
  10. 제1항에 있어서, 13-아세틸-9-데옥소바카틴 Ⅲ, 9-데옥소파클리탁셀, 13-아세틸-7-데옥시-9-데옥소바카틴 Ⅲ, 7-데옥시-9-데옥소파클리탁셀, 13-아세틸-10-데스아세톡시-7-데옥시-9-데옥소바카틴 Ⅲ 및 10-데스아세톡시-7-데옥시-9-데옥소파클리탁셀로 이루어진 그룹으로부터 선택되는 화합물.
  11. 메틸 13-아세틸-9-디하이드로바카틴 Ⅲ 9-O-크산테이트, 9-데옥소바카틴 Ⅲ, 13-{(2R,3S)-N-벤질옥시카보닐-N,O-(1-메틸에틸리덴)-3-페닐이소세린}-9-데옥소바카틴 Ⅲ, 7-O-트리에틸실실-9-데옥소바카틴 Ⅲ, 13-아세틸-9-데옥소바카틴 Ⅲ 7-티오카보닐이미다졸리드, 7-데옥시-9-데옥소바카틴 Ⅲ, 13-{(2R,3S)-N-벤질옥시카보닐-N,O-(1-메틸에틸리덴)-3-페닐이소세린}-7-데옥시-9-데옥소바카틴 Ⅲ, 7-데옥시-9-데옥소바카틴 Ⅲ 10-티오카보닐이미다졸리드, 10-데스아세톡시-7-데옥시-9-데옥소바카틴 Ⅲ 및 13-{(2R,3S)-N-벤질옥시카보닐-N,O-(1-메틸에틸리덴)-3-페닐이소세린}-10-데스아세톡시-7-데옥시-9-데옥소바카틴 Ⅲ으로 이루어진 그룹으로부터 선택되는 중간체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960705045A 1994-03-09 1995-03-01 9-데옥소탁산 화합물(9-Deoxotaxane compounds) KR970701708A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/208,509 1994-03-09
US08/208,509 US5440056A (en) 1992-04-17 1994-03-09 9-deoxotaxane compounds
PCT/US1995/002524 WO1995024402A1 (en) 1994-03-09 1995-03-01 9-deoxotaxane compounds

Publications (1)

Publication Number Publication Date
KR970701708A true KR970701708A (ko) 1997-04-12

Family

ID=22774850

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960705045A KR970701708A (ko) 1994-03-09 1995-03-01 9-데옥소탁산 화합물(9-Deoxotaxane compounds)

Country Status (15)

Country Link
US (2) US5440056A (ko)
EP (1) EP0749432B1 (ko)
JP (1) JPH09511235A (ko)
KR (1) KR970701708A (ko)
AT (1) ATE201019T1 (ko)
AU (1) AU688946B2 (ko)
CA (1) CA2182103A1 (ko)
DE (1) DE69520880T2 (ko)
DK (1) DK0749432T3 (ko)
ES (1) ES2158093T3 (ko)
GR (1) GR3036286T3 (ko)
IL (1) IL112880A0 (ko)
PH (1) PH31271A (ko)
PT (1) PT749432E (ko)
WO (1) WO1995024402A1 (ko)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
US5990325A (en) 1993-03-05 1999-11-23 Florida State University Process for the preparation of 9-desoxotaxol, 9-desoxobaccatin III and analogs thereof
US5721268A (en) * 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5710287A (en) * 1991-09-23 1998-01-20 Florida State University Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
US6495704B1 (en) 1991-09-23 2002-12-17 Florida State University 9-desoxotaxanes and process for the preparation of 9-desoxotaxanes
US6018073A (en) * 1991-09-23 2000-01-25 Florida State University Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US6011056A (en) 1991-09-23 2000-01-04 Florida State University C9 taxane derivatives and pharmaceutical compositions containing them
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
FR2696459B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
US5973160A (en) 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
US6339164B1 (en) 1993-01-29 2002-01-15 Florida State University C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6710191B2 (en) 1993-03-05 2004-03-23 Florida State University 9β-hydroxytetracyclic taxanes
ATE232854T1 (de) * 1993-03-05 2003-03-15 Univ Florida State Verfahren zur herstellung von 9-desoxotaxanen
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US6262054B1 (en) 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US5688977A (en) * 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
JP2000510470A (ja) 1996-05-06 2000-08-15 フロリダ・ステイト・ユニバーシティ １―デオキシバッカチンｉｉｉ、１―デオキシタキソールおよび１―デオキシタキソール類似体、ならびにこれらの製造方法
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US7288665B1 (en) * 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
DE69812395T2 (de) 1997-08-21 2004-02-05 Florida State University, Tallahassee Verfahren zur synthese von taxanen
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
AU1374601A (en) * 1999-11-12 2001-05-30 Angiotech International Ag Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
PL366100A1 (en) 2000-09-22 2005-01-24 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
EP2014307A3 (en) 2001-03-13 2010-12-08 Angiotech International Ag Micellar drug delivery vehicles and uses thereof
PT1392254E (pt) 2001-04-20 2007-06-29 Univ British Columbia Sistemas de distribuição micelares de fármacos para fármacos hidrofóbicos.
EP1435965A4 (en) * 2001-09-26 2005-09-21 Intermune Inc PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
JP2006513152A (ja) * 2002-10-09 2006-04-20 ファイトジェン ライフ サイエンシズ インコーポレイテッド 新規タキサンならびにその使用および調製に関する方法
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US7202370B2 (en) * 2003-10-27 2007-04-10 Conor Medsystems, Inc. Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
SI1720540T1 (sl) 2004-02-18 2008-12-31 Gpc Biotech Ag Satraplatin za zdravljenje rezistentnih ali refraktornih tumorjev
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US20080146555A1 (en) 2004-06-18 2008-06-19 Gpc Biotech, Inc Uses of Kinase Inhibitors and Compositions Thereof
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
USH2260H1 (en) 2005-02-17 2011-07-05 Angiotech International Ag Stents combined with paclitaxel derivatives
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US7847111B2 (en) * 2006-06-19 2010-12-07 Canada Inc. Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III
EP2043704B2 (en) 2006-06-30 2017-04-19 Cook Medical Technologies LLC Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
US9198893B2 (en) 2008-05-22 2015-12-01 Galera Labs, Llc Combination antitumor therapy
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
SG11202007317XA (en) 2018-01-31 2020-08-28 Galera Labs Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CN112368011A (zh) 2018-04-11 2021-02-12 俄亥俄州创新基金会 缓释微粒用于眼用药物递送的方法和组合物
CN113226389B (zh) 2018-11-14 2022-11-08 乐通公司 在经改性设备表面上具有药物洗脱涂层的医疗设备
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
AU2020348457A1 (en) 2019-09-19 2022-04-07 Leap Therapeutics, Inc. Use of DKK-1 inhibitors for treating cancer
WO2021102403A1 (en) 2019-11-22 2021-05-27 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5416225A (en) * 1992-03-30 1995-05-16 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol
CA2130578A1 (en) * 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
IL108316A (en) * 1993-01-15 2006-10-31 Univ Florida State History of C-10 Texan and pharmaceuticals containing them

Also Published As

Publication number Publication date
US5440056A (en) 1995-08-08
DE69520880D1 (de) 2001-06-13
PH31271A (en) 1998-06-18
DK0749432T3 (da) 2001-07-30
AU688946B2 (en) 1998-03-19
PT749432E (pt) 2001-09-28
JPH09511235A (ja) 1997-11-11
EP0749432A1 (en) 1996-12-27
CA2182103A1 (en) 1995-09-14
EP0749432B1 (en) 2001-05-09
MX9603891A (es) 1997-07-31
ES2158093T3 (es) 2001-09-01
GR3036286T3 (en) 2001-10-31
AU3104795A (en) 1995-09-25
ATE201019T1 (de) 2001-05-15
US5616740A (en) 1997-04-01
DE69520880T2 (de) 2001-12-20
WO1995024402A1 (en) 1995-09-14
IL112880A0 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
KR970701708A (ko) 9-데옥소탁산 화합물(9-Deoxotaxane compounds)
IL107553A0 (en) Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
FI924227A0 (fi) Nya alkoxisubstituerade taxaner och farmaceutiska kompositioner innehaollande dessa.
MX9302214A (es) Derivados de taxol y proceso para su preparacion
AU2212292A (en) Novel furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
ATE243688T1 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
KR910006200A (ko) 퀴논 유도체 및 약리학적 이용
ATE209034T1 (de) Taxolderivate
SI9520078B (sl) Polsintetski taksani z antitumorsko aktivnostjo
DE69402694D1 (de) Taxolderivate, deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
IL91913A0 (en) Fluorosubstituted benzene derivatives,processes for the preparation thereof and diagnostic compositions containing the same
PT90125A (pt) Processo para a preparacao de derivados de benzopirano
SE8206499L (sv) Azino-rifamyciner och forfarande for framstellning derav
DE3866292D1 (de) Piperazinylalkylpiperazindion-derivate, ihre verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE69131774D1 (de) Antibakterielle penem-ester derivate
DE69511401D1 (de) Wässrige beschichtungszusammensetzungen
KR920000856A (ko) 폴리올레핀용 청징제 이를 함유하는 폴리올레핀 조성물
KR920700030A (ko) 진양성 조성물
ATE132867T1 (de) 20,21-dinoreburnaminderivate, substituiert in position 15, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende zusammensetzungen

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960909

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20000229

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20020429

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20020918

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20020429

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I